艾迪注射液降低胃癌患者化疗过程中骨髓抑制发生率及其影响因素的研究  

Effects of Aidi Injection on Reducing the Incidence of Myelosuppression in Gastric Cancer Patients During Chemotherapy and Its Influencing Factors

作　　者：谢刚 张静 卢今[1] XIE Gang;ZHANG Jing;LU Jin(Dept.of Pharmacy,Infection Hospital of Anhui Provincial Hospital(Hefei Infectious Disease Hospital),Hefei 230001,China;The Key Laboratory of Anti-inflammatory and Immune Medicine,Ministry of Education/Institute of Clinical Pharmacology,Anhui Medical University/The First Affiliated Hospital of Anhui Medical University,Hefei 230032,China)

机构地区：[1]安徽省立医院感染病院(合肥市传染病医院)药剂科,合肥230001 [2]抗炎免疫药物教育部重点实验室/安徽医科大学临床药理研究所/安徽医科大学第一附属医院,合肥230032

出　　处：《中国医院用药评价与分析》2023年第6期673-677,681,共6页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：抗炎免疫药物教育部重点实验室2021年度开放课题资助项目(No.KFJJ-2021-05)。

摘　　要：目的:探讨艾迪注射液对胃癌患者化疗过程中骨髓抑制发生率及严重程度的影响,为临床合理用药提供参考。方法:选取2016年6月至2022年1月安徽医科大学第一附属医院收治的接受化疗的胃癌住院患者1860例,使用倾向性评分匹配的方法1∶1分为艾迪组与对照组,每组410例。回顾性对比两组患者化疗前后白细胞、血小板水平及其抑制率,并通过Logistic回归进一步分析骨髓抑制的影响因素和艾迪注射液的作用,通过分层分析艾迪注射液的适用性。结果:两组患者均完成4次标准化疗(若化疗后患者白细胞/血小板水平处于Ⅱ—Ⅳ级,认定为发生白细胞/血小板抑制),艾迪组患者历次化疗后白细胞抑制率分别为2.44%(10/410)、8.78%(36/410)、8.78%(36/410)和13.41%(55/410),血小板抑制率分别为0%(0/410)、4.63%(19/410)、4.88%(20/410)和4.88%(20/410);对照组患者的白细胞抑制率为9.27%(38/410)、20.98%(86/410)、21.71%(89/410)和27.56%(113/410),血小板抑制率为2.20%(9/410)、3.90%(16/410)、5.37%(22/410)和5.61%(23/410),组间比较的差异均有统计学意义(P<0.05)。化疗后,艾迪组患者的白细胞计数明显高于对照组;第2、3次化疗后,艾迪组患者的血小板计数明显高于对照组,差异均有统计学意义(P<0.05)。回归分析结果显示,艾迪注射液是降低白细胞、血小板抑制率的独立影响因素(P<0.01)。分层分析结果显示,艾迪注射液对于不同特征的患者均有较好的疗效。结论:艾迪注射液能够降低化疗所致骨髓抑制的发生率,并减轻其骨髓抑制的严重程度。OBJECTIVE:To explore the effects of Aidi injection on the incidence and severity of myelosuppression in patients with gastric cancer during chemotherapy,so as to provide reference for rational drug use in clinic.METHODS:A total of 1860 inpatients with gastric cancer who received chemotherapy admitted into the First Affiliated Hospital of Anhui Medical University from Jun.2016 to Jan.2022 were extracted to be divided into the Aidi group and control group by the method of propensity score matching 1∶1,with 410 patients in each group.The levels of leukocytes and platelets and its inhibitory rates before and after chemotherapy were retrospectively compared between two groups.Logistic regression was used to further analyze the influencing factors of myelosuppression and the effect of Aidi injection,the applicability of Aidi injection was analyzed by stratification.RESULTS:Two groups of patients all completed three cycles of standard chemotherapy.The rates of leukocyte inhibition and platelet inhibition were respectively 2.44%(10/410),8.78%(36/410),8.78%(36/410)and 13.41%(55/410),and the rates of platelet inhibition were respectively 0%(0/410),4.63%(19/410),4.88%(20/410)and 4.88%(20/410);in the control group,the rates of leukocyte inhibition were respectively 9.27%(38/410),20.98%(86/410),21.71%(89/410)and 27.56%(113/410),and the rates of platelet inhibition were respectively 2.20%(9/410),3.90%(16/410),5.37%(22/410)and 5.61%(23/410),with statistically significant differences(P<0.05).After chemotherapy,the level of white blood cell count in the Aidi group was significantly higher than that in the control group.After the second and third chemotherapy,the level of platelet count in Aidi group was significantly higher than that in control group,with statistically significant differences(P<0.05).Regression analysis showed that Aidi injection was an independent factor in reducing the rate of leukocyte and platelet inhibition(P<0.01).Stratified analysis showed that Aidi injection had significant efficacy on patients with dif

关 键 词：艾迪注射液 胃癌 骨髓抑制 白细胞 血小板 

分 类 号：R979.1[医药卫生—药品]